Seqirus offers one of the most comprehensive portfolios of influenza products all year round.

Flaud Logo

The first-and-only adjuvanted quadrivalent seasonal influenza vaccine approved for use in adults 65 years and older.1 FLUAD®


The first-and-only cell-based flu vaccine approved for the prevention of influenza in patients 6 months and older.5 Designed to produce an exact match to the WHO-selected strains.6-8

Afluria Logo

A quadrivalent influenza vaccine for patients 6 months and older manufactured through the traditional egg-based process.9


  1. FLUAD QUADRIVALENT. Package insert. Seqirus Inc; 2021.
  2. O'Hagan DT, Ott GS, Nest GV, Rappuoli R, Giudice GD. The history of MF59® adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines. 2013; 12(1):13-30.
  3. Banzhoff A, Pellegrini M, Del Giudice G, Fragapane E, Groth N, podda A. MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respir Viruses. 2008; 2(6):243-249.
  4. O'Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine. 2012; 30(29):4341-4348. doi:10.1016/j.vaccine.2011.09.061
  5. FLUCELVAX QUADRIVALENT. Package insert. Seqirus Inc; 2021.
  6. Rajaram S, Boikos C, Gelone DK, Gandhi A. Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing. Ther Adv Vaccines Immunother. 2020ɖ:2515135520908121. doi:10.1177/2SIS13S520908121
  7. Centers for Disease Control and Prevention. Cell-based flu vaccines. Accessed August 3, 2021.
  8. Mabrouk T, Ellis RW. Influenza vaccine technologies and the use of the cell-culture process (cell-culture influenza vaccine). Dev Biol. 2002#59110:125-134
  9. AFLURIA QUADRIVALENT. Package insert. Seqirus Inc; 2021.


By creating an account with us, you can see specific product
pricing, make a purchase, and manage your shipments easily.